Compare TYRA & TGLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | TGLS |
|---|---|---|
| Founded | 2018 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2021 | 2011 |
| Metric | TYRA | TGLS |
|---|---|---|
| Price | $30.63 | $45.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $47.50 | ★ $63.33 |
| AVG Volume (30 Days) | ★ 725.7K | 237.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.41% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $370,984,000.00 |
| Revenue This Year | N/A | $13.56 |
| Revenue Next Year | N/A | $9.04 |
| P/E Ratio | ★ N/A | $61.61 |
| Revenue Growth | N/A | ★ 17.98 |
| 52 Week Low | $9.96 | $37.52 |
| 52 Week High | $40.65 | $83.32 |
| Indicator | TYRA | TGLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 52.45 |
| Support Level | $29.68 | $40.88 |
| Resistance Level | $30.70 | $46.81 |
| Average True Range (ATR) | 1.71 | 1.64 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 16.17 | 57.95 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Tecnoglass Inc is a manufacturer of hi-spec architectural glass and windows for residential and commercial construction industries, operating through its direct and indirect subsidiaries. Its product offerings include tempered glass, laminated glass, thermo-acoustic glass, sliding windows, projecting windows, guillotine windows, sliding doors, loating facades, automatic doors, bathroom dividers, and commercial display windows, among others. The company has one operating segment, Architectural Glass and Windows, which is also its reporting segment. Geographically, the company generates maximum revenue from its customers in the United States, followed by Colombia, Panama, and other regions.